Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase NA 1Phase EARLY_PHASE1 1Phase 2/3 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Classical hematology 1

Conditions

Ovarian Neoplasms 1Iron Deficiencies 1Carcinoma, Ovarian Epithelial 1Anemia, Iron-Deficiency 1Anemia 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 154Carboplatin 146Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × Ferric Oxide, Saccharated × Clear all
NCT03933813 2023-01-05

Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients

University of Wisconsin, Madison

Phase 1/2 Terminated
9 enrolled
Classical hematologyGynecologic

Carcinoma, Ovarian Epithelial, Iron Deficiencies, Anemia, Ovarian Neoplasms, Anemia, Iron-Deficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡